CellCentric
Neil Pegg is a seasoned professional with over three decades of experience in the pharmaceutical and biotech industries. Currently serving as the Chief Scientific Officer and Research & Operations Director at CELLCENTRIC LIMITED since January 2009, Neil has held significant roles at various companies, including Director of Chemistry at Piramed Pharma and OSI Pharmaceuticals, and Research Director at ReOx Ltd. Neil's academic background includes a BSc in Chemistry from the University of Bristol, a PhD in Synthesis of Natural Products from the University of Nottingham, and a Postdoctoral fellowship at The Ohio State University focusing on Taxanes.
This person is not in any teams
This person is not in any offices
CellCentric
CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.